Plastic and reconstructive surgery increasingly depends on data-driven instruments to improve clinical decision-making. Machine learning (ML), through its capacity to analyze intricate, high-dimensional data, presents novel prospects for forecasting surgical outcomes with enhanced accuracy compared to traditional statistical models. This systematic study evaluates the extent, efficacy, and methodological rigor of ML applications in plastic and reconstructive surgery, encompassing burn treatment, microsurgical reconstruction, and breast surgery. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 standards, we searched four main databases for research published between January 2015 and March 2025. Eligible papers used ML models to predict clinical outcomes in plastic or reconstructive surgery and provided quantifiable performance indicators. Data were retrieved using the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) and Prediction Model Risk of Bias Assessment Tool (PROBAST) frameworks, then synthesized narratively. We included eleven studies that had more than 34,000 patients. Random forests, neural networks, and gradient boosting have emerged as the most prevalent and highest-performing models, with several attaining AUCs exceeding 0.90. Notwithstanding encouraging outcomes, the majority of research depended on internal validation, with only one performing external validation. Calibration reporting and data transparency were constrained. The majority of studies exhibited a high or moderate risk of bias. In summary, ML models provide significant prediction accuracy in plastic surgery; yet, they are limited by methodological deficiencies that impede clinical implementation. Future initiatives must prioritize external validation, repeatability, and ethical execution to facilitate the safe and successful incorporation into surgical practice.
Hematological biomarkers have emerged as powerful tools in diagnosing Acute Heart Failure (AHF). This study introduces a novel diagnostic framework that integrates Explainable Artificial Intelligence (XAI) with Morris Sensitivity Analysis (MSA) to enhance both the interpretability and performance of machine learning models in AHF detection. A dataset consisting of 425 AHF patients and 430 controls was analyzed using eight machine learning models, including XGBoost, Histogram-based Gradient Boosting (histGB), Explainable Boosting Machine (EBM), and Random Forest. Model performance was evaluated through metrics such as AUC, accuracy, precision, recall, and Brier score. Hyperparameters were optimized via Bayesian optimization. Feature importance was assessed using MSA to identify variables with the highest predictive influence. The histGB model achieved the highest performance with an AUC of 87.93%. Both MSA and EBM consistently identified PDW, RDW-CV, NEU, NEU/LY ratio, age, and WBC as top predictive features across multiple models. These hematological markers demonstrated strong potential for early diagnosis and risk stratification in AHF patients. This study presents a clinically relevant, interpretable, and cost-effective diagnostic strategy that combines XAI with MSA for AHF prediction. The framework enhances clinical trust and provides a pathway toward personalized treatment by identifying accessible hematological biomarkers. The integration of explainability into AI models improves their transparency and applicability in real-world clinical settings.
Frontiers in Public Health · مجلد 12 · 1462693-1462693
Fetal health holds paramount importance in prenatal care and obstetrics, as it directly impacts the wellbeing of mother and fetus. Monitoring fetal health through pregnancy is crucial for identifying and addressing potential risks and complications that may arise. Early detection of abnormalities and deviations in fetal health can facilitate timely interventions to mitigate risks and improve outcomes for the mother and fetus. Monitoring fetal health also provides valuable insights into the effectiveness of prenatal interventions and treatments. For fetal health classification, this research work makes use of cardiotocography (CTG) data containing 21 features including fetal growth, development, and physiological parameters such as heart rate and movement patterns with three target classes "normal," "suspect," and "pathological." The proposed methodology makes use of data upsampled using the synthetic minority oversampling technique (SMOTE) to handle the class imbalance problem that is very crucial in medical diagnosing with a light gradient boosting machine. The results show that the proposed model gives 0.9989 accuracy, 0.9988 area under the curve, 0.9832 recall, 0.9834 precision, 0.9832 F1 score, 0.9748 Kappa score, and 0.9749 Matthews correlation coefficient value on the test dataset. The performance of the proposed model is compared with other machine learning models to show the dominance of the proposed model. The proposed model's significance is further evaluated using 10-fold cross-validation and comparing the proposed model with other state-of-the-art models.
fetal health classificationcardiotocographyLightGBMSHAP explainable AI
BACKGROUND: This study aims to identify unique metabolomics biomarkers associated with Type 2 Diabetes (T2D) and develop an accurate diagnostics model using tree-based machine learning (ML) algorithms integrated with bioinformatics techniques. METHODS: Univariate and multivariate analyses such as fold change, a receiver operating characteristic curve (ROC), and Partial Least-Squares Discriminant Analysis (PLS-DA) were used to identify biomarker metabolites that showed significant concentration in T2D patients. Three tree-based algorithms [eXtreme Gradient Boosting (XGBoost), Light Gradient Boosting Machine (LightGBM), and Adaptive Boosting (AdaBoost)] that demonstrated robustness in high-dimensional data analysis were used to create a diagnostic model for T2D. RESULTS: As a result of the biomarker discovery process validated with three different approaches, Pyruvate, D-Rhamnose, AMP, pipecolate, Tetradecenoic acid, Tetradecanoic acid, Dodecanediothioic acid, Prostaglandin E3/D3 (isobars), ADP and Hexadecenoic acid were determined as potential biomarkers for T2D. Our results showed that the XGBoost model [accuracy = 0.831, F1-score = 0.845, sensitivity = 0.882, specificity = 0.774, positive predictive value (PPV) = 0.811, negative-PV (NPV) = 0.857 and Area under the ROC curve (AUC) = 0.887] had the slight highest performance measures. CONCLUSIONS: ML integrated with bioinformatics techniques offers accurate and positive T2D candidate biomarker discovery. The XGBoost model can successfully distinguish T2D based on metabolites.
type 2 diabetesmetabolomics biomarkersmetabolic signaturesXGBoost
Accurate and rapid diagnosis is essential in the healthcare system for the detection of strokes to mitigate the devastating effects. This study introduces an innovative model for identifying strokes using advanced deep learning (DL) architectures, including SqueezeNet v1.1 and MobileNet V3-Small, feature fusion approaches, and CatBoost models. Using SqueezeNet v1.1 and MobileNet V3-Small, the authors extract meaningful features from computed tomography images that capture local details and global patterns suggesting stroke conditions. Subsequently, they employ feature fusion to combine the complementary representations derived by both architectures, consequently boosting the discriminative capability of the feature set. The Optuna-based CatBoost model is employed to predict stroke using the fused features. The experimental findings show outstanding performance, with a considerable accuracy of 99.1%. The high accuracy level demonstrates our suggested method’s effectiveness in precisely detecting strokes from medical imaging data. Combining DL architectures, feature fusion, and gradient-boosting models offers a promising approach to enhancing stroke diagnosis systems. This can potentially improve patient outcomes and clinical decision-making in stroke treatment.